A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

STATUS

Recruiting
End date

Mar 31, 2025
participants needed

1340
sponsor

Novartis Pharmaceuticals

Send

Updated on 20 September 2024

See if I qualify

alzheimer's disease

mini-mental state examination

mental state examination

apolipoprotein e4

Accepts healthy volunteers

Summary

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

Description

This study will assess the effects of each of the two therapies given separately, both targeting amyloid, on cognition, global clinical status, and underlying pathology in participants at risk for the onset of clinical symptoms of Alzheimer's disease (AD). Cognitively unimpaired individuals with two APOE4 genes and age 60 to 75 years, inclusive, are selected as they represent a population at particularly high risk of progression to Mild Cognitive Impairment and/or dementia due to Alzheimer's disease.

The study follows a randomized, double-blind, placebo-controlled, two-cohort, parallel group design in which participants receive one of the investigational treatments or their matching placebo for at least 60 months up to a maximum of 96 months and no longer than when the target number of events for the TTE endpoint has been observed and confirmed in either cohort.

An unbalanced randomization (active: placebo) of 5:3 ratio in Cohort I (430 CAD106 :260 Placebo) and 3:2 ratio in Cohort II (390 CNP520 : 260 Placebo) will be applied. Randomization will be stratified by age group (60-64 years, 65-75 years) and region (North America/Other , Europe).

Participants who meet study entry requirements will be required to undergo at least one PET scan during the course of the study. Additional PET scans, blood and CSF collection will be voluntary. The study (also known as the Generation Study 1) is conducted as part of the Alzheimer's Prevention Initiative (API) program.

Details

Condition	Alzheimer's Disease
Age	60-75 years
Treatment	CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520
Clinical Study Identifier	NCT02565511
Sponsor	Novartis Pharmaceuticals
Last Modified on	20 September 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Consent to receive disclosure of their risk estimates to develop clinical symptoms of AD based on their APOE genotype
	Male or female, age 60 to 75 years inclusive. Females must be considered post-menopausal and not of child bearing potential
	Mini-Mental State Examination (MMSE) total score 24 (at screening or in previous 3 months) and cognitively unimpaired as evaluated by memory tests performed at screening
	Homozygous APOE4 genotype
	Participant's willingness to have a study partner
Exclusion Criteria
	Any disability that may prevent the participants from completing all study requirements
	Current medical or neurological condition that might impact cognition or performance on cognitive assessments
	Advanced, severe progressive or unstable disease that may interfere with the safety, tolerability and study assessments, or put the participant at special risk
	History of malignancy of any organ system, treated or untreated, within the past 60 months
	History of hypersensitivity to any of the investigational drugs or their excipients / adjuvant or to drugs of similar chemical classes
	Indication for, or current treatment with ChEIs and/or another AD treatment (e.g. memantine)
	Contraindication or intolerance to MRI or PET investigations (with fluorinated radio ligands)
	Brain MRI results showing findings unrelated to AD that, in the opinion of the Investigator might be a leading cause to future cognitive decline, might pose a risk to the participant, or might prevent a satisfactory MRI assessment for safety monitoring
	Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years
	A positive drug screen at Screening, if, in the Investigator's opinion, this is due to drug abuse
	Significantly abnormal laboratory results at Screening, or infection not as a result of a temporary condition
	Current clinically significant ECG findings. For Cohort - I only: Participants with previous organ transplantation or stem cell transplantation, or indication for treatment with anti-coagulants
	For Cohort - II only: Participants with depigmenting or hypopigmenting
	conditions (e.g. albinism vitiligo) or active / history of chronic urticarial
	in the past year

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

alzheimer's disease

mini-mental state examination

mental state examination

apolipoprotein e4

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease